{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}],"title":"Month 6"}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"}],"units":"Participants"}],"description":"Specific primary biochemical tumor markers were used to assess the efficacy of pasireotide in PNETs. A Month 6 responder was defined as the patients who either attained normalization or greater than 50% reduction from baseline in the level of the primary biochemical tumor marker at Month 6.","groups":[{"description":"One of the 10 types of PiNETs analyzed","id":"OG000","title":"All PiNETS (Prolactinoma)"}],"paramType":"NUMBER","populationDescription":"The efficacy analyzable set included all enrolled patients who received at least one dose of pasireotide LAR and had indication-specific baseline primary biochemical tumor marker levels \\>ULN. Responder analysis are reported only for indications with minimum of 6 patients. Patients with missing Month 6 assessment were considered as non-responders.","reportingStatus":"POSTED","timeFrame":"Baseline, month 6","title":"PiNETs: Number of Patients Attaining Normalization or a More Than 50% Reduction in Primary Biochemical Tumor Marker","type":"SECONDARY","unitOfMeasure":"Participants"}